“We are pleased to report a strong start to the year, achieving 11 per cent annual organic ARR growth and 25 per cent adjusted EBITDA as a percentage of revenue,” said Dan Matlow, CEO, VitalHub Corp. announced its financial results for the first quarter ended March 31, 2026.
Matlow said the company’s recent acquisitions are supporting growth, with integration efforts progressing well as VitalHub continues to improve operational efficiency and strengthen its balance sheet to expand acquisition capacity.
The healthcare software provider delivered robust top-line growth during the quarter, with revenue rising 47 per cent year-on-year to $31.9 million, compared with $21.7 million in the corresponding period last year.
Annual recurring revenue (ARR) reached $99.1 million as of March 31, 2026, up 34 per cent from $73.7 million a year earlier and 3 per cent sequentially from $96.1 million at the end of 2025.
The company said year-on-year ARR growth was driven by 11 per cent organic expansion, 22 per cent contribution from acquisitions and favourable foreign exchange movements.
Quarter-over-quarter ARR growth was primarily supported by organic gains of $2.7 million.
VitalHub also reported improved profitability.
Net income rose to $2.36 million for the quarter, compared with $1.16 million in the prior-year period.
Net income before income taxes increased to $3.6 million from $1.49 million.
EBITDA more than doubled to $6.53 million from $3.15 million a year earlier.
Adjusted EBITDA climbed 42 per cent to $7.99 million, representing 25 per cent of revenue, compared with $5.61 million or 26 per cent of revenue in Q1 2025.
Gross profit margin improved to 82 per cent, up from 80 per cent in the same quarter last year.
The company also continued to strengthen its liquidity position, with cash, cash equivalents and short-term investments rising to $121.3 million as of March 31, 2026, compared with $119.2 million at the end of December 2025.
VitalHub said strong billings and renewal activity across its business contributed to the quarter’s performance.
The company’s strategy remains focused on expanding its healthcare technology portfolio through both organic growth and acquisitions, while integrating recently acquired businesses to drive further operational efficiencies.
